Evidence map›Paper›PMID 40353969›Full record

ArticleDoklady. Biochemistry and biophysics2025

Immunophenotypes of Systemic Lupus Erythematosus-Features of Clinical and Laboratory Disorders.

A S Avdeeva, A P Aleksankin, E V Chetina, Yu N Gorbunova, T V Popkova, G A Markova, T A Panafidina, E L Nasonov

Abstract read
PubMed Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

A S AvdeevaNasonova Research Institute of Rheumatology, Moscow, Russia. 9056249400@mail.ru.
A P AleksankinNasonova Research Institute of Rheumatology, Moscow, Russia.
E V ChetinaNasonova Research Institute of Rheumatology, Moscow, Russia.
Yu N GorbunovaNasonova Research Institute of Rheumatology, Moscow, Russia.
T V PopkovaNasonova Research Institute of Rheumatology, Moscow, Russia.
G A MarkovaNasonova Research Institute of Rheumatology, Moscow, Russia.
T A PanafidinaNasonova Research Institute of Rheumatology, Moscow, Russia.
E L NasonovNasonova Research Institute of Rheumatology, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveto evaluate subpopulations of B lymphocytes and features of interferon (IFN) status in patients with systemic lupus erythematosus (SLE), to clarify the relationship of immunological parameters with clinical manifestations of the disease. MATERIALS AND

methods: A total of 139 patients (123 women (88%) and 16 men (12%)) with a definite diagnosis of SLE were included in the analysis. The disease duration was 3.0 [0.3; 12.0] years, SLEDAI-2K 7 [4; 11] points, SDI 0 [0; 1] points. Immunophenotyping of peripheral blood lymphocytes, including determination of B cells, the general population of memory B cells, non-switched and switched memory B cells, naive, transient B cells, and plasmablasts was carried out using multicolor flow cytometry. IFN status was assessed by the expression of IFN-stimulated genes (MX1, RSAD2, and EPSTI1) using real-time polymerase chain reaction.

results. Two immunological "patterns" were identified-the prevailing immunological mechanism of the pathogenesis of the disease (SLE) with predominant activation of type I IFN and with predominant activation of the B-cell component of the immune system. The immunological phenotype with activation of type I IFN was associated with high immunological activity, predominant skin damage, and leukopenia, whereas the phenotype with predominant activation of the B-cell component was associated with damage to the kidneys and nervous system.

conclusions. The results of the work suggest a wide variety of immune mechanisms underlying the pathogenesis of SLE. It is possible to identify a number of leading molecular "patterns" of the pathogenesis of the disease, which must be taken into account to select an effective "targeted" drug.

Indexed as

B-LymphocytesImmunophenotypingLupus Erythematosus, SystemicAdultFemaleHumansMaleMiddle AgedB lymphocyte subpopulationsimmunophenotypeinterferon signaturesystemic lupus erythematosus

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.